poradic hemiplegic migraine (SHM) is a subtype of hemiplegic migraine, characterized by episodes of migraine with a reversible motor aura, without a positive family history, and is a mimicker of an atypical severe form of migraine, stroke, epilepsy, multiple sclerosis, metabolic disorders, or conversion disorder. Case presentation: We present the case of a young 28-year-old female, who had a history of recurrent reversible attacks of headache with sensory aura accompanied with left hemiparesis for the past 5 years, with no positive family history of similar symptoms. The work-up ruled out differential diagnoses and genetic work-up found a novel SCN1A gene missense variation in exon 26 (c.4855A>G; p.Met1619Val) in a case of SHM. She was discharged on flunarizine for prophylaxis. Conclusions: We describe, for the first time, a case of SHM with a mutation in the SCN1A gene.
Hemiplegic migraine (HM) has been classified by the International Headache Society under the heading of migraine with aura (1.2). HM (1.2.3) occurs in two forms: familial (FHM 1.2.3.1) and sporadic (SHM 1.2.3.2). 1 Migraine attacks are associated with a gradual progression of motor weakness/hemiparesis during the aura phase and where no first-or second-degree relative (parent, sibling, or child) has had identical attacks. The complex aura symptoms of fever, lethargy, dysphasia, confusion, hemiparesis, hemisensory symptoms, hemianopia, and scintillating scotoma are associated with the phenotype of SHM, akin to stroke. In lieu of no diagnostic marker, the diagnosis of SHM in most cases is essentially one of exclusion.
Case presentation
A 28-year-old, married, Hindu Asian, right-handed female presented with a history of episodic attacks of headache, along with transient weakness of the left half of her body occurring twice a week for the past 5 years. She had bifrontal, throbbing headache associated with nausea, photophobia, and phonophobia, persisting for 4-6 hours. Each episode was associated with a tingling sensation starting from the left upper limb and involving the left lower limb as well, followed by weakness in a similar distribution. The progression of sensory symptoms took 10-20 minutes to reach its peak and later subsided in the next 30-45 minutes, to be followed by left hemiparesis which, along with the headache, lasted for 4-6 hours with complete recovery. Some episodes were associated with transient diminution of vision and vertigo. No scotomas or flashes of light were experienced.
There was no history of syncope, altered sensorium, confusion, language abnormalities, abnormal body movements during or after the episodes, myoclonus, muscle pains or muscle weakness, connective tissue disorder, coagulation disorders, diabetes mellitus, cardiac disease, abortions, smoking, or illicit drug abuse. There was no history of birth insult. None of the first-and second-degree relatives had similar complaints ( Figure 1 She was treated with flunarizine 10 mg once a day as migraine prophylaxis, and naproxen for acute management.
Conclusion
Our patient had a history of throbbing diffuse headaches accompanied by sensory symptoms and associated hemiparesis. There were no migrainous headache events without accompanying aura. There was no family Our patient had no evidence of meningitis as well as no CSF abnormality.
Although there was the presence of visual blurring in a few episodes, the presence of hemiplegia argues against the diagnosis of basilar migraine, as motor weakness is not part of the aura spectrum accompanying it. In migrainous infarction, on the side of the aura origin, large artery territory stroke is the hallmark. Prolonged hemiparesis associated with MRI evidence of infarction confirms the diagnosis. In the present case, normal brain MRI ruled out migrainous infarction. As an entity, prolonged aura without infarction, the prolonged aura with symptoms and signs lasts for more than 2 weeks without any radiologic evidence of infarction, while in our case the aura was shortlived. Our patient best fits into the diagnosis of migraine with aura and its subtype of SHM, 3, 4 and fulfils the criteria.
Most patients with SHM have 'typical' aura symptoms (visual, sensory, and/or aphasic) associated with motor weakness during the acute attack. [3] [4] [5] The headache can be bilateral and precede the aura, with higher frequency of sensory, aphasic auras. The duration of SHM aura is longer compared with a typical migraine with aura. 4 The aura of SHM comprising acute 
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Case Report Headache US NEUROLOGY hemiplegic attack is always associated with severe headache, while the aura of typical migraine may occur without headache. 4 Minor head trauma can trigger HM, 5 whereas minor head trauma is not a triggering factor of classical migraine with aura. In SHM, pathogenetic mutations in CACNA1A
and ATP1A2 gene loci have been reported. 6 No SCN1A mutation has been yet found.
We report, for the first time, a SCN1A gene missense variation in exon 26 The hypothesis we put forward is that the cortical spreading wave of neuronal and glial depolarization across the cerebral cortex, known as cortical depression, followed by long-lasting suppression of neuronal activity, could be due to excessive firing of neurons expressing mutant Na V 1.1. The Met1619Val missense mutation, causing gain or loss of function, can facilitate initiation and propagation of cortical-spreading depression. The repetitive firing of the channel might enhance the release of the excitatory neurotransmitter glutamate, a critical element in cortical-spreading depression. 11 The management of HM is empirical, and nasal administration of ketamine for acute management of aura and intravenous verapamil for acute headache is used. The use of triptans in HM is still being debated. These drugs are historically contraindicated for the fear of their vasoconstrictor properties that can worsen the aura. 2 However, in a retrospective study by Artto et al., triptans were indicated to be safe and effective for the treatment of the headache in attacks. 12 Case reports of effective treatment with flunarizine, naloxane, verapamil, and acetazolamide form the basis of prophylactic treatment and were found to have beneficial effects in some patients with FHM. 2 
